The questions posed of the Luxembourg tribunal have at least some familiarity to them:
" (1) What are the criteria for deciding whether the product is protected by a basic patent in force in Article 3(a) of Regulation 469/2009/EC;If you would like to comment on this case, please email firstname.lastname@example.org by 17 December 2012. This may interfere with your end-of-year
(2) Are the criteria different where the product is not a combination product, and if so, what are the criteria?
(3) In the case of a claim to an antibody or a class of antibodies, is it sufficient that the antibody or antibodies are defined in terms of their binding characteristics to a target protein, or is it necessary to provide a structural definition for the antibody or antibodies, and if so, how much?".